Leta i den här bloggen

onsdag 29 november 2023

Alkanut ilmetä UK:ssa porsaista ihmiseen sikainfluenssavirusta H1N2 , kertoo The Guardian. WOAH ei vielä sano tästä mitään.

 

Swine flu in the UK: what we know so far

One person found to be infected with H1N2 strain, of which 50 cases have been reported globally since 2005

OIE ei vielä raportoi tästä, kuten Guardian tekee.


 

tisdag 28 november 2023

Onkologia:circZFAND6


. 2023 Jul 1:324:121745. doi: 10.1016/j.lfs.2023.121745. Epub 2023 Apr 29.

EIF4A3-induced circZFAND6 promotes breast cancer proliferation and metastasis through the miR-647/FASN axis

Affiliations
Abstract

Aims: Circular RNAs (circRNAs) are important regulators in breast cancer progression. However, the underlying mechanism of circRNAs functions in breast cancer remain largely unclear.

Main methods: To investigate the circRNAs expression pattern in breast cancer, high-throughput circRNA microarray assay was used. The top up-regulated circRNA, circZFAND6, was submitted to further experiments, including cell counting kit-8 (CCK-8) assay, colony formation assay, transwell assay and mouse xenograft assay. To investigate the underlying mechanism of circZFAND6 function in breast cancer progression, luciferase reporter assay and RNA immunoprecipitation (RIP) assay were conducted.

Key findings: We found a novel circRNA, circZFAND6, was up-regulated in breast cancer tissues and cell lines. Inhibition of circZFAND6 reduced proliferation and metastasis of breast cancer. Mechanically, circZFAND6 acted as a competing endogenous RNA (ceRNA) to sponge miR-647 and increase fatty acid synthase (FASN) expression. And eukaryotic translation initiation factor 4A3 (EIF4A3) was found to bind to circZFAND6 pre-mRNA transcript upstream region, leading to the high expression of circZFAND6 in breast cancer. Inhibition of EIF4A3 also suppressed proliferation and metastasis of breast cancer.

Significance: EIF4A3-induced circZFAND6 up-regulation promoted proliferation and metastasis of breast cancer through the miR-647/FASN axis. Our results uncovered a possible mechanism underlying breast cancer progression and might provide a breast cancer treatment target.

Keywords: Breast cancer; EIF4A3; FASN; circZFAND6; miR-647.

PubMed Disclaimer

Onkologia:Anoikis resistanssi . Anoikis on rintasyöpämetastasoinnin transkriptionaali suppressori eli vaimentaja ykkönen(1)

 Anoikis, mikä se on? Anoikis prosessi on inadekvaattia kiinnittymistä, adheesiota, substraattiin . Anoikis prosessin säätelystä  ja metastaasiprosessin  vaimentamisesta  on kyse Geeni BRMS1 funktiossa. Kts.artikkeli:  https://pubmed.ncbi.nlm.nih.gov/30409762/

HAKU Gene Cards: 28.11. 2023

Aliases for BRMS1 Gene

  • GeneCards Symbol: BRMS1 2
  • BRMS1 Transcriptional Repressor And Anoikis Regulator 2 3 5
  • Breast Cancer Metastasis Suppressor 1 2 3
  • Breast Cancer Metastasis-Suppressor 1 3 4
  • DKFZP564A063 2 5

External Ids for BRMS1 Gene


NCBI Gene Summary for BRMS1 Gene

  • This gene reduces the metastatic potential, but not the tumorogenicity, of human breast cancer and melanoma cell lines. The protein encoded by this gene localizes primarily to the nucleus and is a component of the mSin3a family of histone deacetylase complexes (HDAC). The protein contains two coiled-coil motifs and several imperfect leucine zipper motifs. Alternative splicing results in two transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008]

GeneCards Summary for BRMS1 Gene

BRMS1 (BRMS1 Transcriptional Repressor And Anoikis Regulator) is a Protein Coding gene. Diseases associated with BRMS1 include Breast Cancer and Melanoma. Among its related pathways are Infectious disease and Chromatin organization. Gene Ontology (GO) annotations related to this gene include histone deacetylase binding and histone deacetylase activity. An important paralog of this gene is BRMS1L.

UniProtKB/Swiss-Prot Summary for BRMS1 Gene

Transcriptional repressor. Down-regulates transcription activation by NF-kappa-B by promoting the deacetylation of RELA at 'Lys-310'. Promotes HDAC1 binding to promoter regions. Down-regulates expression of anti-apoptotic genes that are controlled by NF-kappa-B. Promotes apoptosis in cells that have inadequate adherence to a substrate, a process called anoikis, and may thereby inhibit metastasis. May be a mediator of metastasis suppression in breast carcinoma. ( BRMS1_HUMAN,Q9HCU9

Protein details for BRMS1 Gene (UniProtKB/Swiss-Prot)

Protein Symbol:
Q9HCU9-BRMS1_HUMAN
Recommended name: Breast cancer metastasis-suppressor 1

Protein attributes for BRMS1 Gene

Size:246 amino acids
Molecular mass:28461 Da
Protein existence level:PE1
Quaternary structure:

  • Homohexamer (Potential).
    Interacts with SNX6, HDAC1 and RELA.
    Interacts with ARID4A.
    Identified in mSin3A corepressor complexes together with SIN3A, SIN3B, RBBP4, RBBP7, SAP30, SUDS3, ARID4A, HDAC1 and HDAC2.
    Interacts with SPOP; this recruits the protein to a ubiquitin ligase complex containing SPOP and CUL3.

 

Post-translational modifications for BRMS1 Gene

  • Ubiquitinated by a cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex containing SPOP, leading to proteasomal degradation. ( Q9HCU9-BRMS1_HUMAN )
  • Ubiquitination at Lys123 ( NX_Q9HCU9 [NX_Q9HCU9-1] )
  • Modification sites at PhosphoSitePlus ( Q9HCU9

Molecular function for BRMS1 Gene according to UniProtKB/Swiss-Prot

Function:
  • Transcriptional repressor.
    Down-regulates transcription activation by NF-kappa-B by promoting the deacetylation of RELA at 'Lys-310'.
    Promotes HDAC1 binding to promoter regions.
    Down-regulates expression of anti-apoptotic genes that are controlled by NF-kappa-B.
    Promotes apoptosis in cells that have inadequate adherence to a substrate, a process called anoikis, and may thereby inhibit metastasis.
    May be a mediator of metastasis suppression in breast carcinoma. BRMS1_HUMAN,Q9HCU9

 


SuperPathway Contained pathways
1 Infectious disease
2 Chromatin organization
3 SARS-CoV-2 Infection
4 RNA Polymerase I Promoter Opening
5 Potential therapeutics for SARS

RNF41 ja USP8 ; ubikitinaasi ja deubikitinaasi(DUB)

 

. 2013 Aug 15;126(Pt 16):3770-81.
doi: 10.1242/jcs.131250. Epub 2013 Jun 7.

Reciprocal cross-regulation between RNF41 and USP8 controls cytokine receptor sorting and processing

Affiliations
Abstract

The mechanisms controlling the steady-state cell surface levels of cytokine receptors, and consequently the cellular response to cytokines, remain poorly understood. The number of surface-exposed receptors is a dynamic balance of de novo synthesis, transport to the plasma membrane, internalization, recycling, degradation and ectodomain shedding. We previously reported that the E3 ubiquitin ligase RING finger protein 41 (RNF41) inhibits basal lysosomal degradation and enhances ectodomain shedding of JAK2-associated cytokine receptors. Ubiquitin-specific protease 8 (USP8), an RNF41-interacting deubiquitylating enzyme (DUB) stabilizes RNF41 and is involved in trafficking of various transmembrane proteins. The present study identifies USP8 as a substrate of RNF41 and reveals that loss of USP8 explains the aforementioned RNF41 effects. RNF41 redistributes and ubiquitylates USP8, and reduces USP8 levels. In addition, USP8 knockdown functionally matches the effects of RNF41 ectopic expression on the model leptin and leukemia inhibitory factor (LIF) receptors. Moreover, RNF41 indirectly destabilizes the ESCRT-0 complex through suppression of USP8. Collectively, our findings demonstrate that RNF41 controls JAK2-associated cytokine receptor trafficking by acting as a key regulator of USP8 and ESCRT-0 stability. Balanced reciprocal cross-regulation of RNF41 and USP8 thus determines whether receptors are sorted for lysosomal degradation or recycling, this way regulating basal cytokine receptor levels.

Keywords: Cathepsin-L cleavage; Ectodomain shedding; Nrdp1; RNF41; Type 1 cytokine receptor; USP8.


USP8

 

Aliases for USP8 Gene

  • GeneCards Symbol: USP8 2
  • Ubiquitin Specific Peptidase 8 2 3 5
  • UBPY 2 3 4 5
  • Ubiquitin Carboxyl-Terminal Hydrolase 8 2 3 4
  • Ubiquitin Isopeptidase Y 2 3 4
  • KIAA0055 2 4 5
  • SPG59 2 3 5
  • Ubiquitin-Specific-Processing Protease 8 3 4
  • Deubiquitinating Enzyme 8 3 4
  • HumORF8 2 3
  • Ubiquitin Specific Protease 8 2
  • Ubiquitin Thiolesterase 8 3
  • Ubiquitin Thioesterase 8 4
  • EC 3.4.19.12 4
  • EC 3.1.2.15 48
  • HUMORF8 5
  • PITA4 3
  • HUBPy 4

NCBI Gene Summary for USP8 Gene

  • This gene encodes a protein that belongs to the ubiquitin-specific processing protease family of proteins. The encoded protein is thought to regulate the morphology of the endosome by ubiquitination of proteins on this organelle and is involved in cargo sorting and membrane trafficking at the early endosome stage. This protein is required for the cell to enter the S phase of the cell cycle and also functions as a positive regulator in the Hedgehog signaling pathway in development. Pseudogenes of this gene are present on chromosomes 2 and 6. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Sep 2013]

GeneCards Summary for USP8 Gene

USP8 (Ubiquitin Specific Peptidase 8) is a Protein Coding gene. Diseases associated with USP8 include Pituitary Adenoma 4, Acth-Secreting and Conn's Syndrome. Among its related pathways are Signaling by ERBB2 and Deubiquitination. Gene Ontology (GO) annotations related to this gene include SH3 domain binding and cysteine-type deubiquitinase activity. An important paralog of this gene is USP32.

UniProtKB/Swiss-Prot Summary for USP8 Gene

Hydrolase that can remove conjugated ubiquitin from proteins and therefore plays an important regulatory role at the level of protein turnover by preventing degradation. Converts both 'Lys-48' an 'Lys-63'-linked ubiquitin chains. Catalytic activity is enhanced in the M phase. Involved in cell proliferation. Required to enter into S phase in response to serum stimulation. May regulate T-cell anergy mediated by RNF128 via the formation of a complex containing RNF128 and OTUB1. Probably regulates the stability of STAM2 and RASGRF1. Regulates endosomal ubiquitin dynamics, cargo sorting, membrane traffic at early endosomes, and maintenance of ESCRT-0 stability. The level of protein ubiquitination on endosomes is essential for maintaining the morphology of the organelle. Deubiquitinates EPS15 and controls tyrosine kinase stability. Removes conjugated ubiquitin from EGFR thus regulating EGFR degradation and downstream MAPK signaling. Involved in acrosome biogenesis through interaction with the spermatid ESCRT-0 complex and microtubules. Deubiquitinates BIRC6/bruce and KIF23/MKLP1. Deubiquitinates BACE1 which inhibits BACE1 lysosomal degradation and modulates BACE-mediated APP cleavage and amyloid-beta formation (PubMed:27302062). ( UBP8_HUMAN,P40818 )

Protein details for USP8 Gene (UniProtKB/Swiss-Prot)

Protein Symbol:
P40818-UBP8_HUMAN
Recommended name:
Ubiquitin carboxyl-terminal hydrolase 8

Protein attributes for USP8 Gene

Size:
1118 amino acids
Molecular mass:
127523 Da
Quaternary structure:

  • Forms a ternary complex with RNF128 and OTUB1.
    Interacts (via C-terminal UCH catalytic domain) with OTUB1 isoform 1.
    Interacts with STAM2 (via SH3 domain).
    Interacts with DNAJB3, EGFR, EPS15, RASGRF1, RNF41, YWHAE, YWHAG and YWHAZ (By similarity).
    Interacts with NBR1, RASGRF1, RNF41 and IST1.
    Associates with the ESCRT-0 complex and with microtubules (By similarity).
    Interacts with BIRC6/bruce and KIF23/MKLP1.
  • (Microbial infection) Interacts with Zika virus non-structural protein 1.

Post-translational modifications for USP8 Gene

  • Phosphorylation of Ser-718 is essential for interaction with YWHAE and for cytosol localization.
    Undergoes dephosphorylation at Ser-718 in the M phase.
    Tyrosine-phosphorylated in its N-terminal half in an EGFR-dependent manner.
    ( P40818-UBP8_HUMAN )
  • Ubiquitinated.
    Inactive form is mostly monoubiquitinated, but polyubiquitination happens too.
    Ubiquitination is increased in EGF-stimulated cells.
    Ubiquitination of active form is undetectable, suggesting a possibility that USP8 deubiquitinates itself, thereby regulating its own function (By similarity).
    ( P40818-UBP8_HUMAN )
  • Modification sites at PhosphoSitePlus ( P40818 )
  • Modification sites at neXtProt ( NX_P40818 )
  • Glycosylation from GlyGen (P40818) 2 sites, 1 O-linked glycan (2 sites)

UniProtKB/Swiss-Prot:

UBP8_HUMAN :
  • The MIT domain is required for endosomal localization, CHMP1B-binding, maintenance of ESCRT-0 stability and EGFR degradation.
  • Belongs to the peptidase C19 family.
Domain:
  • The MIT domain is required for endosomal localization, CHMP1B-binding, maintenance of ESCRT-0 stability and EGFR degradation.
  • The rhodanese domain is sufficient for RNF41-binding.
Family:
  • Belongs to the peptidase C19 family. 

Pathways by source for USP8 Gene

2 PubChem pathways for USP8 Gene
14 Reactome pathways for USP8 Gene
See All 14 »

 

måndag 27 november 2023

RNF41 E3 ubikitiiniligaasi hajoittaa neureguliinireseptoriproteiinia 1,

 

NCBI Gene Summary for RNF41 Gene

  • This gene encodes an E3 ubiquitin ligase. The encoded protein plays a role in type 1 cytokine receptor signaling by controlling the balance between JAK2-associated cytokine receptor degradation and ectodomain shedding. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jun 2011]

GeneCards Summary for RNF41 Gene

RNF41 (Ring Finger Protein 41) is a Protein Coding gene. Among its related pathways are Class I MHC mediated antigen processing and presentation and Signaling by ERBB2. Gene Ontology (GO) annotations related to this gene include ubiquitin-protein transferase activity and acid-amino acid ligase activity. An important paralog of this gene is RNF151.

UniProtKB/Swiss-Prot Summary for RNF41 Gene

Acts as E3 ubiquitin-protein ligase and regulates the degradation of target proteins. Polyubiquitinates MYD88. Negatively regulates MYD88-dependent production of pro-inflammatory cytokines. Can promote TRIF-dependent production of type I interferon and inhibits infection with vesicular stomatitis virus (By similarity). Promotes also activation of TBK1 and IRF3. Involved in the ubiquitination of erythropoietin (EPO) and interleukin-3 (IL-3) receptors. Thus, through maintaining basal levels of cytokine receptors, RNF41 is involved in the control of hematopoietic progenitor cell differentiation into myeloerythroid lineages (By similarity). Contributes to the maintenance of steady-state ERBB3 levels by mediating its growth factor-independent degradation. Involved in the degradation of the inhibitor of apoptosis BIRC6 and thus is an important regulator of cell death by promoting apoptosis. Acts also as a PRKN modifier that accelerates its degradation, resulting in a reduction of PRKN activity, influencing the balance of intracellular redox state. The RNF41-PRKN pathway regulates autophagosome-lysosome fusion during late mitophagy. Mitophagy is a selective form of autophagy necessary for mitochondrial quality control (PubMed:24949970). ( RNF41_HUMAN,Q9H4P4 )

Aliases for RNF41 Gene

Aliases for RNF41 Gene

  • GeneCards Symbol: RNF41 2

  • Ring Finger Protein 41 2 3 5

  • NRDP1 2 3 4 5

  • SBBI03 2 3 5

  • Ring Finger Protein 41, E3 Ubiquitin Protein Ligase 2 3

  • RING-Type E3 Ubiquitin Transferase NRDP1 3 4

  • E3 Ubiquitin-Protein Ligase NRDP1 3 4

  • FLRF 3 4

  • Neuregulin Receptor Degradation Protein-1 3

  • Fetal Liver Ring Finger 3

  • RING Finger Protein 41 4

  • EC 2.3.2.27 4

  • EC 6.3.2 48

External Ids for RNF41 Gene

ERBB3 binds RN41. Kts STRING MEMO1 karttaa


ERBB3 binds RN41. Kts STRING MEMO1 karttaa

/Neuregulin; Engelsk definition

A peptide factor originally identified by its ability to stimulate the phosphorylation the erbB-2 receptor (RECEPTOR, ERBB-2). It is a ligand for the erbB-3 receptor (RECEPTOR, ERBB-3) and the erbB-4 receptor. Variant forms of NEUREGULIN-1 occur through alternative splicing of its mRNA.)



27,11, 2023

Functional genomic characterization of a synthetic anti-HER3 antibody reveals a role for ubiquitination by RNF41 in the anti-proliferative response.

Turowec JP, Lau EWT, Wang X, Brown KR, Fellouse FA, Jawanda KK, Pan J, Moffat J, Sidhu SS. J Biol Chem. 2019 Jan 25;294(4):1396-1409. doi: 10.1074/jbc.RA118.004420. Epub 2018 Dec 6. PMID: 30523157 Free PMC article.
Using an shRNA library targeting enzymes in the ubiquitin proteasome system, we screened for genes that effect response to IgG 95 and uncovered the E3 ubiquitin ligase RNF41 as a driver of IgG 95 anti-proliferative activity. RNF41 has been shown previously to regula …

Dysregulation of the ErbB family of receptor tyrosine kinases is involved in the progression of many cancers. Antibodies targeting the dimerization domains of family members EGFR and HER2 are approved cancer therapeutics, but efficacy is restricted to a subset of tumors and resistance often develops in response to treatment. A third family member, HER3, heterodimerizes with both EGFR and HER2 and has also been implicated in cancer. Consequently, there is strong interest in developing antibodies that target HER3, but to date, no therapeutics have been approved. To aid the development of anti-HER3 antibodies as cancer therapeutics, we combined antibody engineering and functional genomics screens to identify putative mechanisms of resistance or synthetic lethality with antibody-mediated anti-proliferative effects. We developed a synthetic antibody called IgG 95, which binds to HER3 and promotes ubiquitination, internalization, and receptor down-regulation. Using an shRNA library targeting enzymes in the ubiquitin proteasome system, we screened for genes that effect response to IgG 95 and uncovered the E3 ubiquitin ligase RNF41 as a driver of IgG 95 anti-proliferative activity. RNF41 has been shown previously to regulate HER3 levels under normal conditions and we now show that it is also responsible for down-regulation of HER3 upon treatment with IgG 95. Moreover, our findings suggest that down-regulation of RNF41 itself may be a mechanism for acquired resistance to treatment with IgG 95 and perhaps other anti-HER3 antibodies. Our work deepens our understanding of HER3 signaling by uncovering the mechanistic basis for the anti-proliferative effects of potential anti-HER3 antibody therapeutics.

Keywords: E3 ubiquitin ligase; HER3; RNF41; antibody; antibody engineering; cancer; cell signaling; functional genomics; protein engineering; short hairpin RNA (shRNA); ubiquitylation (ubiquitination).

Protein details for RNF41 Gene (UniProtKB/Swiss-Prot)

Protein Symbol:
Q9H4P4-RNF41_HUMAN
Recommended name:
E3 ubiquitin-protein ligase NRDP1
Protein Accession:
Q9H4P4
Secondary Accessions:
  • A6NFW0
  • B2RBT8
  • O75598

Protein attributes for RNF41 Gene

Size:
317 amino acids
Molecular mass:
35905 Da
Protein existence level:
PE1
Quaternary structure:

  • Interacts with USP8, ERBB3, PRKN and BIRC6.
    Interacts with CSF2RB, EPOR, IL3RA, MYD88 and TBK1.
    Interacts with CLEC16A (By similarity).
Sequence caution:

  • The sequence AAG01988.1 differs from that shown. Reason: Erroneous initiation Truncated N-terminus

Post-translational modifications for RNF41 Gene

  • Autoubiquitinated.
    Autoubiquitination leads to proteasomal degradation.
    Deubiquitinated by USP8 to get stabilized which induces apoptosis.
    ( Q9H4P4-RNF41_HUMAN )
  • Ubiquitination at Lys174 ( NX_Q9H4P4 [NX_Q9H4P4-1] )
  • Modification sites at PhosphoSitePlus ( Q9H4P4 )




Candesartan , Cilaxetil, Covid-19, Ca mammae . Näkökohtia RAS systeemistä

 

Review
. 2020 May 27;9(6):1336.
doi: 10.3390/cells9061336.

The Network of Angiotensin Receptors in Breast Cancer

Affiliations
Free PMC article
Abstract

The renin-angiotensin system (RAS) is a network of proteins regulating many aspects of human physiology, including cardiovascular, pulmonary, and immune system physiology. The RAS is a complicated network of G-protein coupled receptors (GPCRs) (i.e., AT1R, AT2R, MASR, and MRGD) orchestrating the effects of several hormones (i.e., angiotensin II, angiotensin (1-7), and alamandine) produced by protease-based transmembrane receptors (ACE1 and ACE2). Two signaling axes have been identified in the RAS endocrine system that mediate the proliferative actions of angiotensin II (i.e., the AT1R-based pathway) or the anti-proliferative effects of RAS hormones (i.e., the AT2R-, MAS-, and MRGD-based pathways). Disruption of the balance between these two axes can cause different diseases (e.g., cardiovascular pathologies and the severe acute respiratory syndrome coronavirus 2- (SARS-CoV-2)-based COVID-19 disease). It is now accepted that all the components of the RAS endocrine system are expressed in cancer, including cancer of the breast. Breast cancer (BC) is a multifactorial pathology for which there is a continuous need to identify novel drugs. Here, I reviewed the possible roles of both axes of the RAS endocrine network as potential druggable pathways in BC. Remarkably, the analysis of the current knowledge of the different GPCRs of the RAS molecular system not only confirms that AT1R could be considered a drug target and that its inhibition by losartan and candesartan could be useful in the treatment of BC, but also identifies Mas-related GPCR member D (MRGD) as a druggable protein. Overall, the RAS of GPCRs offers multifaceted opportunities for the development of additional compounds for the treatment of BC.

Keywords: AT1R; AT2R; MASR; MRGD; angiotensin; breast cancer.

PubMed Disclaimer

Rintasyövän insidenssi Covid -pandemian aikana hahmottumassa

doi: 10.1016/j.canep.2023.102481. Online ahead of print.

Impact of the COVID-19 pandemic on breast cancer incidence and tumor stage in the Netherlands and Norway: A population-based study

Affiliations
Free article

Abstract

Background: Comparing the impact of the COVID-19 pandemic on the incidence of newly diagnosed breast tumors and their tumor stage between the Netherlands and Norway will help us understand the effect of differences in governmental and social reactions towards the pandemic.

Methods: Women newly diagnosed with breast cancer in 2017-2021 were selected from the Netherlands Cancer Registry and the Cancer Registry of Norway. The crude breast cancer incidence rate (tumors per 100,000 women) during the first (March-September 2020), second (October 2020-April 2021), and Delta COVID-19 wave (May-December 2021) was compared with the incidence rate in the corresponding periods in 2017, 2018, and 2019. Incidence rates were stratified by age group, method of detection, and clinical tumor stage.

Results: During the first wave breast cancer incidence declined to a larger extent in the Netherlands than in Norway (27.7% vs. 17.2% decrease, respectively). In both countries, incidence decreased in women eligible for screening. In the Netherlands, incidence also decreased in women not eligible for screening. During the second wave an increase in the incidence of stage IV tumors in women aged 50-69 years was seen in the Netherlands. During the Delta wave an increase in overall incidence and incidence of stage I tumors was seen in Norway.

Conclusion: Alterations in breast cancer incidence and tumor stage seem related to a combined effect of the suspension of the screening program, health care avoidance due to the severity of the pandemic, and other unknown factors.

Keywords: Breast cancer; COVID-19; Incidence;..

SARS-Cov-2, furiinin pilkkoma kohta PRRA ja MEMO 1-rakenne

 https://pubmed.ncbi.nlm.nih.gov/37990144/

 


. 2023 Nov 21;24(1):71.
doi: 10.1186/s12863-023-01169-8.

Probable human origin of the SARS-CoV-2 polybasic furin cleavage motif

Affiliations
Free PMC article

Abstract

Background: The key evolutionary step leading to the pandemic virus was the acquisition of the PRRA furin cleavage motif at the spike glycoprotein S1/S2 junction by a progenitor of SARS-CoV-2. Two of its features draw attention: (i) it is absent in other known lineage B beta-coronaviruses, including the newly discovered coronaviruses in bats from Laos and Vietnam, which are the closest known relatives of the covid virus; and, (ii) it introduced the pair of arginine codons (CGG-CGG), whose usage is extremely rare in coronaviruses. With an occurrence rate of only 3%, the arginine CGG codon is considered a minority in SARS CoV-2. On the other hand, Laos and Vietnam bat coronaviruses contain receptor-binding domains that are almost identical to that of SARS-CoV-2 and can therefore infect human cells despite the absence of the furin cleavage motif.

Results: Based on these data, the aim of this work is to provide a detailed sequence analysis between the SARS-CoV-2 S gene insert encoding PRRA and the human mRNA transcripts. The result showed a 100% match to several mRNA transcripts. The set of human genes whose mRNAs match this S gene insert are ubiquitous and highly expressed, e.g., the ATPase F1 (ATP5F1) and the ubiquitin specific peptidase 21 (USP21) genes; or specific genes of target organs or tissues of the SARS-CoV-2 infection (e.g., MEMO1, SALL3, TRIM17, CWC15, CCDC187, FAM71E2, GAB4, PRDM13). Results suggest that a recombination between the genome of a SARS-CoV-2 progenitor and human mRNA transcripts could be the origin of the S gene 12-nucleotide insert encoding the S protein PRRA motif.

Conclusions: The hypothesis of probable human origin of the SARS-CoV-2 polybasic furin cleavage motif is supported by: (i) the nature of human genes whose mRNA sequence 100% match the S gene insert; (ii) the synonymous base substitution in the arginine codons (CGG-CGG); and (iii) further spike glycoprotein PRRA-like insertions suggesting that the acquisition of PRRA may not have been a single recombination event.

Keywords: Bioinformatics; Human mRNA transcripts; Polybasic furin cleavage motif; SARS-CoV-2; Spike glycoprotein insertions.

PubMed Disclaimer

 

(Huom: MEMO1 on essentielli HER-2 välitteisissä  positiivisissa inflammatorisissa rintasyövissä).